Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Shire news

15 May 2015 Shire Named One of America’s Most Reputable Companies by Reputation Institute
15 May 2015 Shire Recognizes HAE Day with Launch of Interactive Website Calling for Inspirational Wishes
12 May 2015 Block Listing Application
11 May 2015 Shire to Present New Research at American Psychiatric Association Annual Meeting
06 May 2015 Shire to participate at the Deutsche Bank 40th Annual Healthcare Conference
06 May 2015 Jeff Poulton appointed as Chief Financial Officer - Principle terms of remuneration
04 May 2015 Shire and Foundation Fighting Blindness Announce New Research Agreement
01 May 2015 Director/PDMR Share Dealings
01 May 2015 Total Voting Rights
30 Apr 2015 Jeff Poulton Appointed Shire Chief Financial Officer and Joins Board of Directors
30 Apr 2015 Shire delivers strong revenue growth and cash generation; 20% increase in Non GAAP earnings per ADS
28 Apr 2015 Results of the 2015 Annual General Meeting (47KB PDF)
21 Apr 2015 Shire to announce first quarter 2015 results
09 Apr 2015 U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults
09 Apr 2015 Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with Alagille Syndrome
07 Apr 2015 Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD
06 Apr 2015 Shire Comments on USPTO Petitions Related to LIALDA and GATTEX
01 Apr 2015 Natpara® (parathyroid hormone) for Injection Now Available in the U.S.
01 Apr 2015 Total Voting Rights
31 Mar 2015 Director/PDMR Share Dealings
26 Mar 2015 2014 Annual Report - DTR 6.3.5 Disclosure
26 Mar 2015 Shire and Cincinnati Children’s Establish Rare Disease Research Collaboration
23 Mar 2015 Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) 10 mg Now Available as a Titration Dose
09 Mar 2015 Block Listing Application
04 Mar 2015 Director Declaration
03 Mar 2015 Director/PDMR Shareholding
02 Mar 2015 Elections for Interim Dividend in Respect of the Six Months to December 31, 2014
02 Mar 2015 Shire Submits Application to the U.S. FDA for Approval of Lifitegrast For Treatment of Dry Eye Disease in Adults
02 Mar 2015 Total Voting Rights
25 Feb 2015 Shire to Present at the Cowen 35th Annual Healthcare Conference
24 Feb 2015 Shire Acquires Meritage Pharma
23 Feb 2015 Shire calls for improved rare disease diagnosis on Rare Disease Day 2015
21 Feb 2015 Shire Completes Acquisition of NPS Pharma
13 Feb 2015 Director/PDMR Share Dealings
12 Feb 2015 Shire delivers record revenues and Non GAAP earnings per ADS in 2014, and enters 2015 with strongest-ever pipeline
04 Feb 2015 Shire to announce Full Year 2014 results
03 Feb 2015 Director/PDMR Share Dealings
03 Feb 2015 Tennis Star Monica Seles Partners with Shire to Raise Awareness of Binge Eating Disorder in Adults
02 Feb 2015 Total Voting Rights
30 Jan 2015 Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder
27 Jan 2015 U.S. Supreme Court Grants Shire Petition
26 Jan 2015 Shire’s investigational SHP609, idursulfase-IT, receives FDA Fast Track designation for the treatment of neurocognitive decline associated with Hunter syndrome
23 Jan 2015 Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone)
22 Jan 2015 Positive response from European Decentralised Procedure for Elvanse Adult® in adults with ADHD
21 Jan 2015 Shire Added to Global 100 Sustainability Index
11 Jan 2015 Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech
08 Jan 2015 Director/PDMR Share Dealings
06 Jan 2015 Shire to Present at 33rd Annual J.P. Morgan Healthcare Conference
02 Jan 2015 Total Voting Rights
02 Jan 2015 Director/PDMR Share Dealings

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device